Genetic Atypical Hemolytic Uremic Syndrome Causing Kidney Transplant Failure (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO1187; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "She was treated with eculizumab, pulse steroids, rituximab, and IVIg; however, graft function declined and dialysis was restarted. After the second transplant, likely triggers for recurrent aHUS include ischemia-reperfusion injury, calcineurin inhibitors, or graft infection. This case highlights the risk of recurrent TMA in patients with complement-mediated HUS and the importance of sustained complement inhibition therapy in the peri-transplant setting."
Antibody-mediated Rejection • Atypical Hemolytic Uremic Syndrome • Cardiovascular • Chronic Kidney Disease • Complement-mediated Rare Disorders • Glomerulonephritis • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Ischemic stroke • Lupus • Lupus Nephritis • Nephrology • Pulmonary Embolism • Reperfusion Injury • Systemic Lupus Erythematosus • Thrombosis • Transplantation
|
|
Joseph Taylor; Marina Magdy Tawadrous; Rupinder Kaur; Lauren Su; Sapna Shah
|